Details for Patent: 9,370,581
✉ Email this page to a colleague
Which drugs does patent 9,370,581 protect, and when does it expire?
Patent 9,370,581 protects AMVUTTRA and is included in one NDA.
This patent has forty-three patent family members in six countries.
Summary for Patent: 9,370,581
| Title: | Carbohydrate conjugates as delivery agents for oligonucleotides |
| Abstract: | The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)- or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; RN is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S. |
| Inventor(s): | Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash Nair, Martin Maier |
| Assignee: | Alnylam Pharmaceuticals Inc |
| Application Number: | US14/329,540 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 9,370,581
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 9,370,581 | ⤷ Start Trial | Y | Y | AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,370,581
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008333811 | ⤷ Start Trial | |||
| Australia | 2008340354 | ⤷ Start Trial | |||
| Australia | 2008340355 | ⤷ Start Trial | |||
| Canada | 2708153 | ⤷ Start Trial | |||
| Canada | 2708171 | ⤷ Start Trial | |||
| Canada | 2708173 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
